Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform. News about RenovoRx often highlights progress in both its commercial activities and its clinical development programs.
Investors following RNXT news can expect regular updates on the commercialization of RenovoCath as a stand‑alone targeted drug‑delivery device, including adoption trends among cancer centers, repeat purchase orders, and the expansion of institutions approved to purchase the device. Company announcements also describe physician interest and growing clinical demand for localized, arterial drug‑delivery approaches in solid tumors.
Another major news theme is RenovoRx’s ongoing Phase III TIGeR‑PaC trial, which evaluates intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer. Press releases cover clinical milestones, pharmacokinetic and pharmacodynamic sub‑study results, and abstract acceptances and presentations at scientific meetings such as the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
RenovoRx news also includes updates on its post‑marketing observational registry study collecting real‑world safety and survival data in solid tumors, as well as its support of investigator‑initiated trials in borderline resectable and metastatic or oligometastatic pancreatic cancer. In addition, the company reports on corporate developments such as Scientific Advisory Board appointments, participation in investor and industry conferences, and capital markets activities disclosed in SEC filings.
For readers tracking RNXT, this news stream provides ongoing insight into how RenovoRx is advancing its TAMP platform, expanding RenovoCath’s commercial footprint, and generating clinical evidence around its drug‑device combination candidate IAG.
RenovoRx (Nasdaq: RNXT) reported accelerating commercial adoption of its FDA-cleared RenovoCath device, with 12 U.S. cancer centers now using the device and 33 centers requesting access — a threefold increase in the near-term sales pipeline since Q1 2025.
RenovoCath has been used in 700+ procedures since 2014, the Company expects at least 10 new patients to begin TAMP therapy in Q1 2026, and the board appointed Ramtin Agah, MD to Executive Chairman to support commercialization and clinical adoption.
RenovoRx (Nasdaq: RNXT) announced acceptance of a clinical data abstract for presentation at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting April 11–15, 2026 in Toronto. The abstract examines PET/CT metabolic response after transarterial microperfusion using the TAMP therapy platform in locally advanced pancreatic cancer.
Presentation is scheduled for April 13, 2026, 4:45–5:45 PM ET (Abstract No. 2229370) and was submitted by a multidisciplinary team including Dr. Mustafa Al-Roubaie of Moffitt Cancer Center.
RenovoRx (NASDAQ: RNXT) formed a dedicated RenovoCath Medical Advisory Board (MAB) to guide clinical and market strategy for its FDA-cleared RenovoCath device and TAMP therapy platform. The MAB unites leading U.S. interventional radiology experts to advise on investigator-initiated trials, real-world evidence, and commercialization within cleared indications.
The board will inform ongoing trials including a Phase III TIGeR-PaC study and a post-marketing registry, and support capital-efficient clinical study planning to broaden TAMP applications in hard-to-treat cancers.
RenovoRx (Nasdaq: RNXT) appointed Mark Voll as Chief Financial Officer, effective February 1, 2026. Voll brings 30+ years of financial leadership and experience scaling public companies through IPOs and exits.
He will support commercialization of RenovoCath, provide forward-facing stockholder communications, and help advance the Phase III TIGeR-PaC clinical trial. A transitional finance team will include Ronald B. Kocak and Lilly Huang.
RenovoRx (NASDAQ: RNXT) will present new clinical data on February 6, 2026 at the SIO Annual Scientific Meeting showing that the TAMP™ therapy platform can use a simplified external pressure transducer to obtain reliable intra-arterial pressure measurements during double-balloon RenovoCath procedures.
The study (Abstract 303) showed strong correlation to intravascular pressure wire measurements in a porcine model and found peak pressure is affected by controllable variables like balloon spacing and target vessel diameter, highlighting procedural optimization opportunities.
RenovoRx (Nasdaq: RNXT) announced acceptance of a clinical data abstract for presentation at the 2026 Society of Interventional Oncology Annual Scientific Meeting in Savannah, Feb 4–8, 2026.
The ePoster, presented Feb 6, 2026, examines real-time intravascular pressure measurements using the TAMP therapy platform and the FDA-cleared RenovoCath double-balloon catheter to optimize targeted chemotherapy delivery in solid tumors.
RenovoRx (Nasdaq: RNXT) announced expansion of commercial adoption of its FDA-cleared RenovoCath device from five active U.S. cancer centers in September 2025 to nine as of Jan 20, 2026, including City of Hope Cancer Center and Moffitt Cancer Center. The RenovoCath device enables the company’s TAMP™ localized chemotherapy delivery approach and is being integrated into oncology programs while related physician interviews and patient stories were publicized. RenovoRx reported approximately $900,000 in sales through September 2025 and says it built a dedicated commercial team by end of 2025 to accelerate adoption. Ongoing Phase III TIGeR-PaC trial sites are not counted among current commercial customers but could convert after full enrollment in H1 2026.
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will present at the AlphaNorth Capital Event on January 16-18, 2026 in Nassau, Bahamas. Mr. Bagai will provide updates on commercial adoption of RenovoCath (an FDA-cleared targeted drug-delivery device) and progress in the Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine for locally advanced pancreatic cancer (LAPC). He will also discuss a post-marketing observational registry collecting real-world safety and survival data across solid tumors and support for capital-efficient investigator-initiated trials in pancreatic cancer.
Investor one-on-one meetings can be requested via KCSA Strategic Communications.
RenovoRx (Nasdaq: RNXT) announced new pharmacokinetic (PK) and pharmacodynamic (PD) data from a Phase III TIGeR-PaC sub-study presented at ASCO GI 2026. The 16-patient sub-study compared intra-arterial gemcitabine (IAG) delivered via the TAMP therapy platform (11 patients) to standard IV gemcitabine (5 patients).
Key findings: IAG showed reduced systemic gemcitabine levels, increased inactive metabolite levels, and a correlation between higher metabolite levels and reduced CA 19-9 biomarker. The company says this profile may improve local potency and lower systemic side effects while the TIGeR-PaC trial continues to enroll and evaluates overall survival.
RenovoRx (Nasdaq: RNXT) announced acceptance of a clinical data abstract at the ASCO Gastrointestinal Cancers Symposium 2026 for a pharmacokinetic/pharmacodynamic sub-study of the Phase III TIGeR-PaC trial.
The sub-study, led by Dr. Paula Novelli, compares intra-arterial gemcitabine delivered via RenovoCath (IAG) to standard intravenous gemcitabine in locally advanced pancreatic cancer and reports decreased systemic drug levels consistent with a reduced clinical side-effect profile for the localized TAMP therapy approach.
The poster (Abstract 732, Poster Board K2) will be presented on January 9, 2026 at Moscone West, San Francisco, during Poster Session B.